Viking Takes Obesity Candidate into Phase III to Rival Lilly, Novo

With promising Phase II data in hand, Viking Therapeutics is pushing its subcutaneous GLP-1/GIP receptor dual agonist into late-stage development, the company announced on Wednesday.